Tags

Type your tag names separated by a space and hit enter

Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013.
Diagn Microbiol Infect Dis. 2015 May; 82(1):78-84.DM

Abstract

A total of 4533 isolates from community-acquired respiratory tract infections (CARTIs) and 8446 from skin and skin structure infections (SSSIs) were consecutively collected in 149 US medical centers in 2013. Strains were susceptibility tested by broth microdilution method against ceftaroline and numerous comparators. Ceftaroline (MIC(50/90), ≤0.015/0.12 μg/mL) was more potent than ceftriaxone (MIC(50/90), ≤0.06/1 μg/mL) against Streptococcus pneumoniae and highly active against ceftriaxone-nonsusceptible strains (n=201; MIC(90), 0.25 μg/mL). Ceftaroline was also very active against Haemophilus influenzae (MIC(50/90), 0.008/0.015 μg/mL), methicillin-susceptible (MIC(50/90), 0.25/0.25 μg/mL) and methicillin-resistant Staphylococcus aureus (MIC(50/90), 1/1 μg/mL), and β-hemolytic streptococci (highest MIC, 0.03 μg/mL). Ceftaroline exhibited good activity against non-extended-spectrum β-lactamase (ESBL) phenotype isolates of Klebsiella spp. and Escherichia coli (96.7% susceptible and MIC(90) of 0.25 μg/mL for both) but limited activity against ESBL phenotype isolates. In summary, ceftaroline exhibited potent in vitro activity against a large collection of bacterial isolates causing CARTI and SSSI in US medical centers.

Authors+Show Affiliations

JMI Laboratories, North Liberty, IA, USA. Electronic address: helio-sader@jmilabs.com.JMI Laboratories, North Liberty, IA, USA.JMI Laboratories, North Liberty, IA, USA.JMI Laboratories, North Liberty, IA, USA.JMI Laboratories, North Liberty, IA, USA.JMI Laboratories, North Liberty, IA, USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25708896

Citation

Sader, Helio S., et al. "Antimicrobial Activity of Ceftaroline Tested Against Bacterial Isolates Causing Respiratory Tract and Skin and Skin Structure Infections in US Medical Centers in 2013." Diagnostic Microbiology and Infectious Disease, vol. 82, no. 1, 2015, pp. 78-84.
Sader HS, Farrell DJ, Mendes RE, et al. Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013. Diagn Microbiol Infect Dis. 2015;82(1):78-84.
Sader, H. S., Farrell, D. J., Mendes, R. E., Flamm, R. K., Castanheira, M., & Jones, R. N. (2015). Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013. Diagnostic Microbiology and Infectious Disease, 82(1), 78-84. https://doi.org/10.1016/j.diagmicrobio.2015.01.015
Sader HS, et al. Antimicrobial Activity of Ceftaroline Tested Against Bacterial Isolates Causing Respiratory Tract and Skin and Skin Structure Infections in US Medical Centers in 2013. Diagn Microbiol Infect Dis. 2015;82(1):78-84. PubMed PMID: 25708896.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013. AU - Sader,Helio S, AU - Farrell,David J, AU - Mendes,Rodrigo E, AU - Flamm,Robert K, AU - Castanheira,Mariana, AU - Jones,Ronald N, Y1 - 2015/02/10/ PY - 2014/12/19/received PY - 2015/01/27/revised PY - 2015/01/30/accepted PY - 2015/2/25/entrez PY - 2015/2/25/pubmed PY - 2016/1/12/medline KW - Cephalosporin KW - MRSA KW - Staphylococcus aureus KW - Streptococcus pneumoniae SP - 78 EP - 84 JF - Diagnostic microbiology and infectious disease JO - Diagn Microbiol Infect Dis VL - 82 IS - 1 N2 - A total of 4533 isolates from community-acquired respiratory tract infections (CARTIs) and 8446 from skin and skin structure infections (SSSIs) were consecutively collected in 149 US medical centers in 2013. Strains were susceptibility tested by broth microdilution method against ceftaroline and numerous comparators. Ceftaroline (MIC(50/90), ≤0.015/0.12 μg/mL) was more potent than ceftriaxone (MIC(50/90), ≤0.06/1 μg/mL) against Streptococcus pneumoniae and highly active against ceftriaxone-nonsusceptible strains (n=201; MIC(90), 0.25 μg/mL). Ceftaroline was also very active against Haemophilus influenzae (MIC(50/90), 0.008/0.015 μg/mL), methicillin-susceptible (MIC(50/90), 0.25/0.25 μg/mL) and methicillin-resistant Staphylococcus aureus (MIC(50/90), 1/1 μg/mL), and β-hemolytic streptococci (highest MIC, 0.03 μg/mL). Ceftaroline exhibited good activity against non-extended-spectrum β-lactamase (ESBL) phenotype isolates of Klebsiella spp. and Escherichia coli (96.7% susceptible and MIC(90) of 0.25 μg/mL for both) but limited activity against ESBL phenotype isolates. In summary, ceftaroline exhibited potent in vitro activity against a large collection of bacterial isolates causing CARTI and SSSI in US medical centers. SN - 1879-0070 UR - https://www.unboundmedicine.com/medline/citation/25708896/Antimicrobial_activity_of_ceftaroline_tested_against_bacterial_isolates_causing_respiratory_tract_and_skin_and_skin_structure_infections_in_US_medical_centers_in_2013_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732-8893(15)00031-0 DB - PRIME DP - Unbound Medicine ER -